top of page

Free Biopharma Daily Stock Updates - 04/05/22

$XBI $93.25 | -2.96%

 

Covid Updates

$TNXP -4.9% Tonix Pharmaceuticals Announces Extension of Sponsored Research Agreement with Kansas State University to Develop Live-Virus Vaccine Against COVID-19. source



Pipeline Updates

$IOVA -4.6% Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma source


$AGEN -2.7% Agenus’ CD137 Agonist (AGEN2373) Advances in the Clinic, Triggering Milestone Payment from Gilead. source


$ALDX -0.8% Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease. source


$KDNY -11.0% Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and Care. source


$VBIV -4.4% VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program. source


$VRCA +1.6% Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma. source


$TLSA +1.0% FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab. source


$NRIX -0.3% Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors. source


$IMRA -22.1% Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia. source


$SYGGF +1.5% Synairgen to present at ATS 2022. source



Business Updates

$COLL +4.4% Collegium Provides 2022 Financial Guidance. source


$BLUE -3.8% bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US. source


 

Posted by FS/JM

0 comments
bottom of page